Literature DB >> 8757623

Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine.

J H Tian1, L H Miller, D C Kaslow, J Ahlers, M F Good, D W Alling, J A Berzofsky, S Kumar.   

Abstract

The C-terminal 19-kDa, epidermal growth factor-like region of the merozoite surface protein 1 (MSP1) has been used as a vaccine to induce protective immunity to Plasmodium yoelii in mice and to Plasmodium falciparum in monkeys. To analyze the mechanisms and genetic regulation of this MSP1 vaccine-induced protection, we studied the immunologic correlates of protection in H-2 recombinant and congenic mouse strains on the B10 background. Multiple H-2-linked loci were found to contribute, each with a different mechanism. One locus mapped to the I-A region based on the strong protection in C57BL/10 mice compared with intermediate protection in B10.A(4R) mice and the lack of a difference between B10.AKM and B10.MBR mice. Differences in efficacy of passively transferred antisera from vaccinated C57BL/10 vs B10.A(4R) mice indicated that the protection regulated by the I-A locus was at least in part Ab dependent. Two loci mapped to the right of I-A (FE, H-2S, or H-2D) based on a correlation with the number of H-2k loci to the right of I-A in mice that were I-Ak. One effect was Ab independent and may correspond to a possible negative effect of the I-Ek locus. T cells from protected and nonprotected strains differed in their production of IFN-gamma and TNF-alpha following immunization with MSP1(19), but it was unclear how the differential patterns of cytokine expression related to the level of protection. Thus, MSP1(19) vaccine-induced protection is regulated by H-2-linked loci corresponding to two different immune mechanisms. These findings may indicate the need for more than one Ag in a vaccine to protect an HLA-diverse population.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757623

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors.

Authors:  P Vukovic; P M Hogarth; N Barnes; D C Kaslow; M F Good
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.

Authors:  Jiraprapa Wipasa; Huji Xu; Morris Makobongo; Michelle Gatton; Anthony Stowers; Michael F Good
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

3.  Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.

Authors:  M B Joshi; A A Gam; R A Boykins; S Kumar; J Sacci; S L Hoffman; H L Nakhasi; R T Kenney
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).

Authors:  Zhi-Hong Zhang; Pei-Hong Jiang; Ning-Jun Li; Mi Shi; Weida Huang
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

5.  Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii.

Authors:  J H Tian; S Kumar; D C Kaslow; L H Miller
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.

Authors:  Lina Wang; Matthew W Goschnick; Ross L Coppel
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

7.  Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.

Authors:  Shigeto Yoshida; Hiroshi Nagumo; Takashi Yokomine; Hitomi Araki; Ayaka Suzuki; Hiroyuki Matsuoka
Journal:  PLoS One       Date:  2010-10-28       Impact factor: 3.240

8.  Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.

Authors:  S A Kaba; A Price; Z Zhou; V Sundaram; P Schnake; I F Goldman; A A Lal; V Udhayakumar; C W Todd
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

9.  Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination.

Authors:  Danielle I Stanisic; Laura B Martin; Xue Q Liu; David Jackson; Juan Cooper; Michael F Good
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Mary Galinski; Alberto Moreno
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.